Considering a Data-Driven, Risk-Based Approach to Easing COVID-19 Lockdowns Across AmericaPeter Kolchinsky, PhDApr 29, 20204Apr 29, 20204
Published inThe Biotech Social ContractThe strange and special case of epinephrineThe biotech social contract stipulates that all drugs must go generic. But what if genericization is bad for public health?Dec 20, 2018Dec 20, 2018
Published inThe Biotech Social ContractDirect-to-Consumer (DTC) advertising: misnamed, misunderstood, and underappreciatedMaligned by doctors and often parodied, appropriately regulated direct-to-consumer drug advertising is a net positive for American…Dec 20, 2018Dec 20, 2018
Published inThe Biotech Social ContractLet’s Throw a Patent-Burning PartyWhen a drug goes generic, it’s as if society has paid off a mortgageOct 31, 2018Oct 31, 2018
Published inThe Biotech Social ContractUnintended Consequences of “Fairness”: Critically examining the idea of the US referencing EU…Anthony Bower Ph.D. and Peter Kolchinsky, Ph.D.Oct 5, 2018Oct 5, 2018
Published inThe Biotech Social ContractHard Negotiating Tactics: Compulsory Licensing and Willingness to DenyPeter Kolchinsky, Ph.D.Oct 4, 2018Oct 4, 2018
Published inThe Biotech Social ContractThe Favors They Do Us: Charging Less in Other Countries Makes Drugs More Affordable in AmericaPeter Kolchinsky, Ph.D.Oct 4, 2018Oct 4, 2018
Published inThe Biotech Social ContractWhy wait for generics? In praise of me-too drugsPeter Kolchinsky, Ph.DMar 24, 2018Mar 24, 2018
Published inThe Biotech Social ContractFalse Heroes — How PBMs Add Insult to the Injury of Insurance Cost-SharingPeter Kolchinsky, Ph.D.Mar 24, 2018Mar 24, 2018
Published inThe Biotech Social ContractAmerica’s Social Contract with the Biopharmaceutical IndustryPeter Kolchinsky, Ph.D.Dec 27, 20179Dec 27, 20179
